Scrip Asks…What Does 2023 Hold for Biopharma? Part 5: Technological Advances
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. In this article published by Scrip Pharma Intelligence, Sirj Goswami, PhD, CEO and co-founder of InsightRX, shares his perspective on the role of Precision Medicine, and is among more than 70 executives and experts that reveal what they are most excited about on the technology front.
Expectations High For Precision Medicine, Artificial Intelligence, And RNA Technologies
In this article published by Scrip Pharma Intelligence*, Sirj Goswami, Ph.D., CEO and co-founder of InsightRX, shares his perspective on the role of Precision Medicine and is among more than 70 executives and experts that reveal what they are most excited about on the technology front.
“Artificial intelligence and machine learning will catalyze the next breakthroughs in precision medicine by enabling real-time analysis and outcome predictions during a clinical trial,” said Sirj Goswami, CEO of healthcare technology firm InsightRX. “This will empower sponsors with reliable pharmacological and clinical insights about the drug and accelerate the identification of optimal doses across different patient populations. Ultimately, advancements in AI and ML will propel personalized medicine forward by maximizing drug efficacy and safety for patients.”
To read the full article, click here.
*About Scrip Pharma Intelligence
Scrip is the trusted, comprehensive source of business-critical market and competitor insights for the commercial pharmaceutical industry. Researched and written by 40+ journalists and analysts publishing around the clock and located across the globe, our teams cover the spectrum of global commercial news – from licensing to clinical trials to competitor activity.